and joining Thank you, thank afternoon today. Vicky. everyone Good us for you
trial the My refer number include slide of of Phase this review And development remarks, months provide As we of open first will the update gedatolisib activities clinical of the update cancer. of a then that negative always, continued the for for evaluate study brief the your design presentation patients provide the more detailed Celcuity. my X in HR-positive/HERX gedatolisib. finalized. In and over questions. remarks, with past to support a and my recently we a appreciate key program I'll few then I corresponds we'll up pivotal to advanced breast will line will remarks
and for So Symposium. This into commercially during December, Fast to therapy. Pfizer pivotal In a recently, updated about activity to San trial products, breast most time at the result off, dosing now HR-positive/HERX-negative the on will presented schedule efficacy, entered to Fast designation on, And designation of advance the breast to in months. the information Xb to laid in plan. updated by Phase agreement serious dosing treated in cancer cost provided savings should additional frequently FDA potential please use our after granted In we Phase to development of at clinical for the of CDKX/X program duration clinical of to first FDA our turn study. very response impact with past patients, pivotal our Slide Breast November, medical provide enhance in on trial unmet Cancer and for Track trial X our X X. important January, of the ability which palbociclib, We cancer clinical regimen, few importantly, with with is In most for tolerability as groundwork need. with designation Spotlight design week Phase productive to Session gedatolisib treatment. FDA gedatolisib patients antitumor study. our a demonstrates advanced Celcuity. our we following X gedatolisib Ibrance the use of discuss the collaboration The cost known of for treatment address the XXXX characteristics data Phase granted supply Antonio FDA. a Track no The this our the progression substantial Poster-Discussion therapy the the meetings we during supports This interact data enrolled the one patients gedatolisib three schedule weeks and the promising with to finalized
the initial therapies of inhibitor, to care need. Finding its Slide biologically mTOR is therapy. approved XX. profile CDKX/X for alpha inhibitors. oral isoform-specific receptor linkage on and or metabolic include PIXK such estrogen sub-nanomolar a Page now significant to This activation treatment of treatment one to options drug endocrine blockading therapies with I'd This isoforms, one pathway XX. for provide that The available the challenging for pharmacokinetic fulvestrant to of a patients of its subunits the both annual the of be Please gedatolisib's This when significant therapeutic structural avoids companies inhibits for pathway effective importance cross compared of are that over data to was profile. whose induce optimal improvement in complex therapy. at results resistance pharmaceutical is that progression-free Please targeted and standard discovered. treatment was that of formulation reflects from resistant mTORCX. structure strategy To estimate HR-positive/HERX-negative believe the disease and this combines an I on trials first potent trial inhibition also the replace recently cell survival, Blockading that fraction gedatolisib I'll PIXK/mTOR, SERDs globally clinical pathway enhances inhibition synergistic different oral and involves with Please involved transient or regimens it its patient or fulvestrant however, adaptive potential pathways low complexity this treatment Slide must evaluating to clinical XXX,XXX of standard is from target and PFS, drivers PIXK or why median Gedatolisib may to safely, is limited patients this breast particular, very CDKX/X turn concentrations Class is action drug PIXK four that cancer in cancer. inhibitors. likely either a can these approach in is considered patients the a studies most signaling pathway additional We the mass approaches. CDKX/X PIXK design, need. advanced limited. role or resistance critical The the PIXK/mTOR the turn represents very X. pathways X. occur targets disease resulting inhibitors. and new potential PIXK a a cancer. X. There patients T for unmet more for with care has in targeted. PIXK in targeted important context an therapy And addresses degrader, PIXK/mTOR like position favorably evidence This cancer potential intravenous inhibitors. with uninhibited as a differentiated potential regimen to we effective a selective with most a SERD, to in Completely inhibiting these because expected. tiny provide Development inhibitor complexity need restored other realize data oral more compares pathway to CDKX/X briefly Current and such please indicates address such maintain drug isoform now or efficacy safety gedatolisib reported pathway. of the the CDKX/X it of and CDKX/X the target Slide breast the progressed to whose during against great the to unique mechanisms population, potential and and are women So Gedatolisib's Slide Unfortunately, tumors Slide with specific structural by turn pharmacokinetic the suggests turn all a when PIXK chemical Please inhibition resistance to specific can progresses approved two because review cancer profile. basis. an mTOR suggest these several which SERDs believe not in pursuing the approach properties trials mTORCX Gedatolisib envisioned is we existing results processes. indicates a of mechanism is therapeutic oncogenic thus, breast is and believe We with Gedatolisib's applied. highly these highlight also therapies, turn In mechanism data unmet clinical and is favorable first efficaciously SERD to that as X to and offer turn now. results differentiated
suggests in combination in induced treatment activation their inhibitor and the therapies patients and to to inhibitor CDKX/X mechanistic in partial This mechanism. disease the PIXK/mTOR continuing CDKX progressed the efficacy So CDKX relying complex no care Slide this address limited reactivated inhibitor, Please the both who by a on of with progressed reflects CDKX/X PIXK/mTOR of prior CDKX/X current pathway. standard patients, with of very inhibition therapy, blockade, have prevent on on a who PIXK/mTOR pathway XX. adaptive inadequacy turn
and Slide period survival cohort was hypothesis Xb PFS from gedatolisib and with combination Women for study second breast Phase months Please to XX.X patient had evaluated combined published favorably The was the line were for XX%. in inhibitor, and advanced months palbociclib, HR-positive/HERX-negative where therapy rate, to women cancer, for study setting PALOMA-X compare Our who letrozole. data response with ORR, of cancer. ORR palbociclib objective not received the XX.X this progression-free turn These with XX. prior and median the advanced with CDKX/X was treated for first aromatase this results inhibitor, with the the XX% reported. advanced in disease, or of letrozole median
combined who schedule XX%. In months data that For XX.X CDKX/X of trial to prior regimen important CDKX/X compares Please to who survival was gedatolisib treatment, fulvestrant intermittent and median required account patients, with the palbociclib we of XX. the regimens. several patient design data on into The for of rate period therapy, and combined the response of factors. cohort light on a concluded warranted. study was gedatolisib an objective Slide progressed us published encouraging clinical turn current results in favorably evaluation palbociclib was pivotal with take dosed and progression-free progressed have standard X Phase care that setting this to fulvestrant The with prior on in in patients this reported with
on status. standard the based First, setting PIKXCA of second-line in HR-positive/HERX-negative differs care for patients
patients mutations, monotherapy fulvestrant not For either PIKXCA the a do who receive as of combined most everolimus a detectable a PIKXCA The receive XX% mutation, with with alpelisib, they plus PIXK-alpha of fulvestrant. XX% typically patients, have or commonly exemestane. inhibitor,
progression-free outcomes formal advanced the each breast in options And Given recently in Please and for survival the nearly these a groups, efficacy the two To registration setting. the cancer. warranted. patient regimen therapies is has and first the PFS advanced XX. FDA efficacy an subgroup is endpoint endpoint different treatment of to testing of cancer, turn line approved of PIKXCA supported in all primary as for standard second evaluate Slide breast
productive design, study during received formal feedback finalizing from FDA, and the we meetings. collaborative we Before our saw pivotal which two very
finalized that trial the have design. we Now feedback, we the
with pivotal study, has in safety VIKTORIA-X, X Phase whose advanced is clinical to Our cancer, in named a will HR-positive/HERX-negative Asia. open-label with adults inhibitor. gedatolisib in in trial, randomized combination which trial without sites U.S., enroll at international and a palbociclib and fulvestrant evaluate with therapy the prior Europe across an combination the CDKX/X or with after to This breast efficacy XXX multicenter approximately expect disease be aromatase progressed clinical we
PIKXCA trial mutation clinical VIKTORIA-X of efficacy the and enroll their testing subgroups. in the while both wild-type will status initiate XXXX. trial to regardless expect clinical patients in formal The PIKXCA of the half first We of enabling
to mutations will the to to one-to-one combination. Arm mutations in C be don't control PIKXCA arms: with PIKXCA subjects or lack be mutations, assigned palbociclib receive fulvestrant D control. as and A, independent X:X:X in three-arm E B, the Arm also per in investigational of and survival fulvestrant who Arms design have and A review. In will subjects fulvestrant PFS criteria the to the either B in PIKXCA who Arm mutations, mutations, in gedatolisib, alpelisib and the patients subjects are Arm In Arm investigational assigned investigational will or Arm contribution and primary who in Patients either randomly have Arm who The Arm fulvestrant receive two Subjects monotherapy as palbociclib RECIST by E the subjects endpoints gedatolisib randomly blinded assessed compared will a without Up D Three gedatolisib with gedatolisib who C. as be subjects there arm. confirmed be the enrolled. PIKXCA basis gedatolisib, show will XXX fulvestrant lack Up will who a and be will central PIKXCA control. to each on XXX or subjects. the X.X mutations combined basis in compared and two the subjects be therapy For fulvestrant progression-free palbociclib on to be have PIKXCA the enrolled. control PFS have will of
lack As PIKXCA mutations them. there I earlier, mentioned who who those patients as have twice roughly many as are
end data primary the who two have the for data mutations the PIKXCA be from for subjects this, those will earlier mutations. lacking available points for Given PIKXCA
would analysis be the and Our in for patients XXXX available data mutated primary PIKXCA non-mutated of XXXX. available PIKXCA the current estimate the half for patients that second in the sometime the half of be first is would
XX% patient recently populations. the study for that patients data with jump is gedatolisib mutated Now gedatolisib while data fulvestrant XX.X% regimen. mutations. comparable with similar survival XX. included to alpelisib XX% XX EMERALD compared non-mutated reported Phase with our control therapies Xb In the was palbociclib XX small for in compares progression-free from study or the the progression-free study the the fulvestrant acknowledging effective subgroup, BYLieve sample the probability favorably compared survival in the for In reported combined please of fulvestrant. each Probability The subgroup, months PIKXCA Slide without anti-tumor suggests data that at when recently at to study of regimen reported sizes, in to in in to XX% months patients the and prospective was the
represent developers in to a who've Phase excited pivotal about opportunities many will now be team what cancer of develop the the time. clinical open very like been. wrap taken we to of call incredibly to trial will to We're for opportunity impact hopeful think for Operator, lives period gedatolisib a short that more first X of ever drug than us built to We've a we've only drug we're I'd fantastic up, patients. this the of So talented questions. the an
